Pharma-Bio Serv, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q3 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Pharma-Bio Serv, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q3 2010 to Q2 2024.
  • Pharma-Bio Serv, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending July 31, 2024 was $2.6M, a 43.9% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $2.6M -$2.03M -43.9% Jul 31, 2024 10-Q 2024-09-16
Q1 2024 $2.61M -$2.41M -48% Apr 30, 2024 10-Q 2024-06-14
Q4 2023 $2.41M -$1.92M -44.3% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 $3.94M -$1.04M -20.9% Oct 31, 2023 10-Q 2024-09-16
Q2 2023 $4.63M -$172K -3.57% Jul 31, 2023 10-Q 2023-09-14
Q1 2023 $5.03M -$449K -8.2% Apr 30, 2023 10-Q 2023-06-14
Q4 2022 $4.33M -$721K -14.3% Jan 31, 2023 10-Q 2023-03-17
Q3 2022 $4.98M +$369K +8.01% Oct 31, 2022 10-K 2024-01-29
Q2 2022 $4.8M -$5.28M -52.4% Jul 31, 2022 10-Q 2022-09-14
Q1 2022 $5.48M -$4.89M -47.1% Apr 30, 2022 10-Q 2022-06-14
Q4 2021 $5.05M -$4.52M -47.2% Jan 31, 2022 10-Q 2022-03-17
Q3 2021 $4.61M -$5.11M -52.6% Oct 31, 2021 10-K 2023-01-30
Q2 2021 $10.1M +$37.9K +0.38% Jul 31, 2021 10-Q 2021-09-14
Q1 2021 $10.4M +$388K +3.89% Apr 30, 2021 10-Q 2021-06-14
Q4 2020 $9.57M +$1.85M +24% Jan 31, 2021 10-Q 2021-03-17
Q3 2020 $9.73M +$947K +10.8% Oct 31, 2020 10-K 2022-02-11
Q2 2020 $10M +$2.24M +28.7% Jul 31, 2020 10-Q 2020-09-14
Q1 2020 $9.98M +$3.31M +49.7% Apr 30, 2020 10-Q 2020-06-15
Q4 2019 $7.72M +$2.26M +41.4% Jan 31, 2020 10-Q 2020-03-16
Q3 2019 $8.78M +$3.59M +69.1% Oct 31, 2019 10-K 2021-02-01
Q2 2019 $7.8M +$2.62M +50.6% Jul 31, 2019 10-Q 2019-09-16
Q1 2019 $6.66M +$96K +1.46% Apr 30, 2019 10-Q 2019-06-14
Q4 2018 $5.46M -$597K -9.86% Jan 31, 2019 10-Q 2019-03-18
Q3 2018 $5.19M -$1.12M -17.8% Oct 31, 2018 10-K 2020-01-29
Q2 2018 $5.18M -$1.77M -25.4% Jul 31, 2018 10-Q 2018-09-14
Q1 2018 $6.57M -$44.3K -0.67% Apr 30, 2018 10-Q 2018-06-14
Q4 2017 $6.05M +$38.1K +0.63% Jan 31, 2018 10-Q 2018-03-19
Q3 2017 $6.32M -$536K -7.82% Oct 31, 2017 10-K 2019-01-29
Q2 2017 $6.95M -$431K -5.84% Jul 31, 2017 10-Q 2017-09-14
Q1 2017 $6.61M -$1.09M -14.2% Apr 30, 2017 10-Q 2017-06-14
Q4 2016 $6.02M -$1.35M -18.3% Jan 31, 2017 10-Q 2017-03-17
Q3 2016 $6.85M -$595K -7.99% Oct 31, 2016 10-K 2018-01-29
Q2 2016 $7.38M -$303K -3.95% Jul 31, 2016 10-Q 2016-09-14
Q1 2016 $7.7M +$597K +8.4% Apr 30, 2016 10-Q 2016-06-14
Q4 2015 $7.36M +$1.08M +17.1% Jan 31, 2016 10-Q 2016-03-16
Q3 2015 $7.45M +$1.06M +16.6% Oct 31, 2015 10-K 2017-01-31
Q2 2015 $7.68M +$1.29M +20.3% Jul 31, 2015 10-Q 2015-09-14
Q1 2015 $7.11M +$68.7K +0.98% Apr 30, 2015 10-Q 2015-06-15
Q4 2014 $6.29M +$614K +10.8% Jan 31, 2015 10-Q 2015-03-17
Q3 2014 $6.39M -$1.02M -13.8% Oct 31, 2014 10-K 2016-01-29
Q2 2014 $6.39M -$1.67M -20.7% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 $7.04M -$573K -7.52% Apr 30, 2014 10-Q 2014-06-16
Q4 2013 $5.67M -$2.05M -26.5% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 $7.4M -$176K -2.32% Oct 31, 2013 10-K 2015-01-29
Q2 2013 $8.05M +$866K +12.1% Jul 31, 2013 10-Q 2013-09-16
Q1 2013 $7.61M +$667K +9.61% Apr 30, 2013 10-Q 2013-06-14
Q4 2012 $7.72M +$1.97M +34.3% Jan 31, 2013 10-Q 2013-03-18
Q3 2012 $7.58M +$2.72M +55.8% Oct 31, 2012 10-K 2014-01-29
Q2 2012 $7.19M +$3.07M +74.5% Jul 31, 2012 10-Q 2012-09-14
Q1 2012 $6.94M Apr 30, 2012 10-Q 2012-06-14
Q4 2011 $5.75M Jan 31, 2012 10-Q 2012-03-16
Q3 2011 $4.86M +$2.34M +93% Oct 31, 2011 10-K 2013-01-29
Q2 2011 $4.12M Jul 31, 2011 10-Q 2011-09-14
Q3 2010 $2.52M Oct 31, 2010 10-K/A 2012-01-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.